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the literature (Ng, 2002; Dizon et al., 2013, Novo et al., 2015), the largest
being a seventeen-patient case series by Euscher et al. (2008).
In this report we describe an unusual case of high-grade uterine





EWSR1 gene1. IntroductionPrimitive neuroectodermal tumors (PNETs) were ﬁrst described in
1973 by Hart and Earle to denote a group of tumors thought to be de-
rived from fetal neuroectodermal cells and that had morphologic fea-
tures of small round cell tumors with variable degrees of neural, glial,
and ependymal differentiation (Hart and Earle, 1973).
This group of tumors also includes Ewing sarcoma, rhabdomyosar-
coma, small-cell osteosarcoma, neuroblastoma, and hematolymphoid
tumors. Uterine PNET appears to fall into two categories. Some have a
chromosomal translocation of the Ewing sarcoma (EWS) gene on chro-
mosome 22, which 90% of the time creates the EWSR1/FLI1 fusion prod-
uct t(11;22)q24q12 (Delattre et al., 1994). This demonstrates histologic,
inmunochemical, and biologic similarities to the EWS/peripheral prim-
itive neuroectodermal tumor (pPNET). Central type PNETs tend to occur
in children and young adults. They are usually seen along the central
axis, particularly in the soft tissue and bone structures of the chest and
abdomen. However, neuroectodermal tumors have been reported in a
variety of visceral sites and in older adults (O'Sullivan et al., 2001).
Small-cell carcinomas arising in the female genital tract are rare (Kim
et al., 2004).e), ayague@riojasalud.es
dp88@hotmail.com (P. Dieste),
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. This is an open access article underA 60 year-old nulliparous woman with a past medical history of
Raynaud's Syndrome, SLE (Systemic lupus erythematosus), CREST (cal-
cinosis, Raynaud, esophageal dysmotility, sclerodactyly and telangiecta-
sia) and nephrotic syndrome. She presented to her general practitioner
complaining of vaginal bleeding and abdominopelvic pain. A pelvic ul-
trasound revealed an atrophic uterus with 45 mm of haematometra
and 34 mm of diffuse endometrial thickness. Endometrial biopsy
showed a diffuse proliferation of undifferentiated tumor cells. CT and
MRI scan revealed a markedly enlarged uterus with a contiguous mass
in the uterine fundus suggestive of uterine tumor (Fig. 1).
She was referred to Gynaecologic Oncology clinic for deﬁnitive sur-
gical management. The patient underwent an exploratory laparotomy,
radical hysterectomy, bilateral salpingo-oophorectomy and para-aortic
lymphadenectomy. A 10 × 13 cm necrotic mass was found arising
from the fundus (Fig. 2). The uterus contained a diffusely inﬁltrative
tumor in the myometrium with involvement of the endometrium and
serosal surface. The endometrial cavity was occupied by a polypoid
mass with necrosis. Histologic sections demonstrated a poorly
circumscribed tumor with inﬁltrative borders containing poorly differ-
entiated epithelioid and spindle cells with a high nuclear/cytoplasm
ratio (Fig. 3). The tumor also contained many areas of necrosis, massive
vascular invasion and extranodal extension of metastasis in para-aortic
lymph nodes. Several areas revealed tumor in an angiocentric pattern
giving the appearance of pseudorosettes (Fig. 3). CD 99, Fli-1, and
Vimentin were positive on immunohistochemical stains (Fig. 3). Final
pathology revealed high-grade primitive neuroectodermal tumor
and intraoperative ﬁndings were consistent with FIGO stage IV
classiﬁcation.
Following discussion of the patient's case at our multidisciplinary
team discussion meeting, the decision was made to treat the patient
with six cycles of adjuvant carboplatin and etoposide. Response to treat-
ment was followed with physical examination and chest, abdomen and
pelvic CT scan.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. CT (a) andMRI scan (c, d, e) revealed an enlarged uteruswith a contiguousmass in the uterine fundus (a). The PET scan showed an hypermetabolic image in the pelvic regionwith
poorly deﬁnedmorphologyoccupying the cervical stumpand PouchofDouglas, hypermetabolismdeposits in themesentery and peritoneumcompatiblewithmesenteric implants, and an
image in the left pubis that, in this context, could be a metastasis (b).
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then presented to her gynaecologist complaining of vaginal bleeding.
Vaginal cytology and biopsy were positive for inﬁltration by the
neuroectodermal tumor. Follow up CT chest scan revealed, in compari-
son with the previous CT, a pulmonary node of 3 mm on the right and
low segment. Abdominal MRI revealed a pelvic mass in the recto-
uterine pouch of 9.6 × 6.2 cm and minimum growth of two para-
aortic lymph nodes. PET scan showed a hypermetabolic image in the
pelvic region (Fig. 1).Fig. 2. Longitudinal section of the uterus showing a tumor with transmyometrial invasion
and cervical involvement.After receiving 6 cycles of chemotherapy, the patient was admitted
into the hospital via A&E with a history of severe abdominal pain. She
was diagnosed of intestinal subocclusion. An abdomino-pelvic CT was
performed which showed trabeculated cystic pelvic mass of 10 cm
whichwasﬁlling up the entireminor andmajor pelvis. Small bowel dis-
tension and colic frame collapsedwere found. However, it wasunable to
ﬁnd the cause for this. Retroperitoneal lymph nodes were enlarged in
comparison with previous CT.
This admission just coincided with the last chemotherapy cycle of
the ﬁrst line. A discussion was therefore carried out with the oncologist
whether she should start with the second line of chemotherapy (carbo-
taxol). As the chemotherapy causes the secondary pancytopenia, this
treatment was rejected at this moment.
Radiology and cytology revealed the diagnosis of progression, and
radiation was considered in the primary treatment. However, it was
never administered because the patient was admitted two days after
hospital discharge presenting abdominal pain and deceased the same
day, seven months since the diagnosis.
3. Discussion
PNETs can be classiﬁed based on the degree of differentiation, loca-
tion and genetic signatures into peripheral and central types.
Peripheral-type PNET/EWING sarcoma is believed to originate from
neural crest and occur outside of the central nervous system. cPNET/
neuroblastoma are derived from the central neuraxis and involve cen-
tral structures including the brain and spinal cord, and generally lack
the EWSR1 gene rearrangement (Hart and Earle, 1973). The majority
of primary uterine PNETs lack the EWSR1 gene translocation, as in our
case, and therefore resemble a cPNET (Varghese et al., 2006).
PNETs belong to a group of small round cell tumors that are most
commonly found in the central nervous system, soft tissues, or bones
Fig. 3. (a) H&E photo (400×). High-power view of diffusely inﬁltrative tumor cells, arranged in trabeculae and cords, marked atypia and pleomorphism, and numerous mitotic ﬁgures
(arrows). (b) H&E photo (40×). Cells are diffusely arranged with variable amounts of vague nesting and/or trabeculated pattern. Perivascular rosettes in a ﬁbrillary background.
Arrows indicate perineural inﬁltration and vascular invasion. Uterine myometrium inﬁltration by a poorly differentiated tumor with diffuse growth pattern “broadsheet”. The tumor
cells were positive for CD99 Strong reactivity of neoplastic cells for this marker (c), synaptophysin (d), Vimentin (e), FLI-1 (f). H&E photo (400×).
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possibly among the least well characterized and have been reported in
the vagina, cervix, uterus and ovary. The most common site in the fe-
male genital tract is the ovary (Odunsi et al., 2004), and the next
commonest is the uterus. PNET of the uterus, however, is rare, and has
been reported in less than 50 cases in the English literature. Various the-
ories have beenproposed as to the origin of theneuroectodermal tissues
in the uterus. It has been suggested that benign glial tissue is originated
from fetal central nervous system tissue implanted at the time of mis-
carriage. However, the ﬁnding of a glial tumor in a young, nulliparous
patient led to the development of alternate theories, some have pro-
posed that is related to ectopically migrated neural crest cells at the
time of fetal development.
PNET's can present in pure formor admixedwith other components,
including endometrioid adenocarcinoma, adenosarcoma, carcinosarco-
ma (metaplastic carcinoma), and heterologous sarcoma.
Risk factors for uterine PNET are few, but include adolescent or post-
menopausal age, Caucasian or Hispanic race. The most common pre-
senting symptom is abnormal vaginal bleeding, and a uterine mass the
most common ﬁnding on exam.Many uterine PNET cases are diagnosed
at advanced stages highlighting their aggressive nature (Park et al.,
2007). The differential diagnosis of uterine PNETs include tumors
exhibiting neuroectodermal elements found in the central nervoussystem. The diagnosis is based on light microscopic and immunohisto-
chemical evidence of neuroectodermal differentiation, with markers
such as CD99, FLi-1, and Vimentin (Park et al., 2007). CD99 is a highly
speciﬁc marker for PNET. In our case FISH examination was performed
which did not show rearrangement of EWSR1 gene.
In the largest case series on uterine PNETs by Euscher et al., CD99
was positive in seven out of nine cases tested for the marker. Also
none of the 12 cases tested for typical EWSR1 rearrangementwere pos-
itive. However,ﬁve cases of typical gene rearrangement are described in
the literature (Euscher et al., 2008; Blattner et al., 2007).
Von Hippel–Lindau disease (vHLD) has been associated with PNET
tumors. The ﬁrst description of the association of vHLD and a cerebellar
PNET occurred in 1993 (Becker et al., 1993). It was recently revealed
that chromosomal translocation t(11;22)(q24;q12) occurs in most
cases of Ewing's sarcoma. Given this association, genetic testing should
be considered if other risk factors are present.
Due to the rare nature of the uterine PNET and the small number of
case reports in the literature, it is difﬁcult to determine the optimal
course of treatment. Treatment for PNETs has included multimodal
therapy with surgery, adjuvant chemotherapy, and radiation. Because
cases of PNET are so rare, it is also problematic to accurately predict
rates of survival or recurrence of this particular type of malignant
neoplasm.
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on the literature regarding patients diagnosed with Stage IV with the
same features (Euscher et al., 2008). The two year survival of younger
patients and postmenopausal patients has been reported as 75% and
32%, respectively (Odunsi et al., 2004). Factors that portend a poor prog-
nosis for the PNET family of tumors include metastatic disease at pre-
sentation, primary extraosseous tumor, central or pelvic disease, age
at diagnoses of 26 or older, tumor size greater than 8 cm, poor response
to chemotherapy, absence of EWS-FL1 fusion gene, and elevated pre-
treatment LDH (Mittal et al., 2007).
When treatedwith local controlmeasures only (surgery and/or radi-
ation therapy), the disease has a high mortality rate and an 80–90% re-
lapse rate. Although overt metastatic disease is found in fewer than 25%
of patients at the time of diagnosis, subclinical metastatic disease, as in
our case, is assumed to be present in nearly all patients due to this
high relapse rate. Patients treated with surgery and radiation have a re-
lapse rate approaching 90% (Blattner et al., 2007). Multimodal therapy
improves disease free survival, but the optimal chemotherapeutic regi-
men has not yet been demonstrated.
Rather than cytotoxic treatment, in the case of PNET, surgery should
be considered as the ﬁrst step. Total hysterectomy with bilateral
salpingo-oophorectomy with or without chemotherapy and/or radio-
therapy is the usual course of treatment provided. Case reports have
demonstrated long disease-free periods after treatment with platinum
and etoposide therapy alone (Tsai et al., 2012). To the date there is
only one case in the literature using the combination of cisplatin/
etoposide/bevacizumab and favorable response to treatment (forty-
eight months disease-free following intervention). The presence of en-
dothelial proliferation and VEGF positivity within the tumor provides
a rational explanation to the effectiveness of this novel chemotherapy
modality against uterine cPNET (Novo et al., 2015).
4. Conclusion
Uterine tumors with neuroectodermal differentiation, similar to
more common endometrial malignancies, tend to occur in postmeno-
pausal women and frequently present with vaginal bleeding. An
immunohistochemistry panel including cytokeratin, neuroﬁlament,
synaptophysin, and CD99 can highlight neuroectodermal differentiation
and identify tumors for which molecular testing should be considered.
Awareness of the occurrence of PNET in the uterus and its recogni-
tion is important to distinguish it from other tumors that may possess
a different behaviour and treatment. PNET is associated with
advanced-stage disease and follows a potentially aggressive clinical
course. Mortality can be high despite a combination therapy approach.
While there is no consensus for the optimal chemotherapy treatment,
carboplatin and etoposide should be considered as a viable option.Early diagnosis is essential as patients with non-metastatic disease re-
spond relatively well to intense multi-modality treatment.
Due to the rare nature of uterine PNET and few case reports in the lit-
erature, it is difﬁcult to determine the optimal course of treatment. Be-
cause cases of PNET are so rare, it is also problematic to accurately
predict rates of survival or recurrence of this particular type of malig-
nant neoplasm. Prospective clinical trials and studies of more cases
with longer follow-up periods are required to estimate the clinical char-
acteristics and evaluate the efﬁcacy of this treatment schema in the
management of advanced-stage uterine cPNET in the female genital
tract. We should suspect this kind of tumor in healthy patients with a
history of an aggressive and quick tumoral progression. For instance,
our patient had an unremarkable previous gynaecological examination.
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